Related trials
ACCOMPLISH (diabetic subgroup), 2010 - benazepril + amlodipine vs benazepril + hydrochlorothiazide
ACCORD blood pressure, 2010 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie
ROADMAP, 2010 - olmesartan vs placebo
AVOID, 2008 - aliskiren vs placebo
ADVANCE, 2007 - perindopril and indapamide vs placebo
ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie
ALLHAT (lisi vs chlor, diabetic subgroup), 2002 - lisinopril vs chlorthalidone
LIFE (diabetic subgroup), 2002 - losartan vs atenolol
ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002 - amlodipine vs chlorthalidone
IPDM, 2001 - irbesartan vs placebo
IDNT amlodipine, 2001 - amlodipine vs placebo
RENAAL, 2001 - losartan vs placebo
IDNT irbesartan, 2001 - Irbesartan vs placebo
IDNT (irbesartan vs amlodipine), 2001 - Irbesartan vs amlodipine
STOP-2 CCB (diabetic subgroup), 2000 - calcium-channel blocker vs diuretic or beta-blocker
INSIGHT (diabetic subgroup), 2000 - Nifedipine vs coamilozide
ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie
NORDIL (diabetic subgroup), 2000 - Diltiazem vs diuretic or beta-blocker
STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000 - ACE inhibitor vs CCB
HOPE (diabetic subgroup), 2000 - ACE inhibitor vs placebo
STOP-2 ACEI (diabetic subgroup), 2000 - ACE inhibitor vs diuretic or beta-blocker
CAPP (diabetic subgroup), 1999 - captopril vs diuretic or beta-blocker
Syst-Eur (diabetic subgroup), 1999 - nitrendipine vs placebo
ABCD, 1998 - nisoldipine vs enalapril
UKPDS 38, 1998 - captopril or atenolol vs control
See also:
All diabetes clinical trials
All hypertension clinical trials
All clinical trials of anti hypertensive agent
All clinical trials of captopril
|
|
Treatments
Studied treatment |
Captopril initial dose of 50 mg daily given in one or two doses
|
Control treatment |
thiazide diuretic or beta-blocker
initial dose of
atenolol and metoprolol of 50�100 mg once daily. Hydrochlorothiazide was given as 25 mg once daily, and
bendrofluazide as 2�5 mg once daily
|
Patients
Patients |
Patients aged 25-66 years with a measured diastolic blood pressure of 100 mm Hg or more on two occasions; subgroup of diabetic patients |
Method and design
Randomized effectives |
309 / 263 (studied vs. control) |
Design |
Parallel groups |
Blinding |
open with blinded assessment |
Follow-up duration |
6.1 year |
Number of centre |
536 |
Geographic area |
Sweden, Finland |
Primary endpoint |
CV events |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
cardiovascular event (fatal and non fatal)
NA / 10985
NA / 0
0,59 [0,38;0,91]
All cause death
NA / 10985
NA / 0
0,54 [0,31;0,95]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Meta-analysis of all similar trials:
angiotensin renin system blockade in diabetes for all type of patients
anti hypertensive agent in diabetes for type1 and 2 diabetic patients with hypertension
anti hypertensive agent in hypertension for diabetic patients
Reference(s)
-
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanm�ki K, Dahl�f B, de Faire U, M�rlin C, Karlberg BE, Wester PO, Bj�rck JE.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial..
Lancet 1999;353:611-6
Pubmed
|
Hubmed
| Fulltext
|